Resource Logo

Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.


Lancet. 1988 Jul 23;2(8604):186-9. Unique Identifier : AIDSLINE

The safety of an antihaemophilic factor concentrate treated with the organic solvent tri-(n-butyl)phosphate and sodium cholate (factor VIII-SD) was assessed for transmission of non-A, non-B (NANB) hepatitis and human immunodeficiency virus (HIV). Patients enrolled in the study had no previous exposure to blood products made from plasma pools, although 5 had received small quantities of single-donor products. All but 1 had normal alanine aminotransferase (ALT) levels, none had markers of HIV infection, and all had been vaccinated against hepatitis B. After treatment with factor VIII-SD, serum ALT levels and HIV antibody were monitored for up to 1 year. 20 patients received 625 to greater than 40,000 U (total 163,000 U, median dose 3900 U), and 17 of these were followed up for at least 6 months: transmission of either NANB hepatitis or HIV was not observed.

Adolescence Alanine Aminotransferase/BLOOD Child Child, Preschool *Cholic Acids Drug Contamination/*PREVENTION & CONTROL Drug Evaluation Factor VIII/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Hemophilia/THERAPY Hepatitis Viruses/DRUG EFFECTS Human HIV/DRUG EFFECTS Infant *Organophosphorus Compounds *Phosphoric Acid Esters JOURNAL ARTICLE


Information in this article was accurate in November 30, 1988. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.